Click on image to view larger version.

Figure 1 PCI Pharmacology Trials: From the Triple to the Quadruple End Point

The current meta-analysis suggests that the primary end point of percutaneous coronary intervention (PCI) pharmacology trials needs revision. Instead of a triple end point—death, asymptomatic creatine kinase-myocardial band (CK-MB)/symptomatic myocardial infarction (MI), and target vessel revascularization (TVR)—future trials might focus on the quadruple end point, which includes the mortality risk of major bleeding. GPI = glycoprotein IIb/IIIa inhibitor.